XTRA:BAYNPharmaceuticals
Assessing Bayer (XTRA:BAYN) Valuation After Positive OCEANIC STROKE Trial Milestone
Bayer (XTRA:BAYN) is back in focus after confirming that its large Phase III OCEANIC-STROKE trial of asundexian met primary efficacy and safety endpoints, with full results set for presentation at the 2026 International Stroke Conference.
See our latest analysis for Bayer.
Those OCEANIC STROKE headlines arrive after a sharp shift in sentiment, with Bayer’s 30 day share price return of 18.21% and 90 day share price return of 62.34%, while the 1 year total shareholder return of 101.10%...